4.8 Article

SLX4IP acts with SLX4 and XPF-ERCC1 to promote interstrand crosslink repair

期刊

NUCLEIC ACIDS RESEARCH
卷 47, 期 19, 页码 10181-10201

出版社

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkz769

关键词

-

资金

  1. National Institutes of Health/National Cancer Institute (NIH/NCI) [P01CA193124]
  2. Cancer Prevention & Research Institute of Texas [RP160667]
  3. NIH [P01 CA193124, CA157448, CA210929, CA216911, CA216437, P01 CA092584. NIH R35 CA220430]
  4. Pamela and Wayne Garrison Distinguished Chair in Cancer Research
  5. Robert A. Welch Chemistry Chair
  6. Cancer Prevention and Research Institute of Texas
  7. NIH/NCI [P30CA016672]

向作者/读者索取更多资源

Interstrand crosslinks (ICLs) are highly toxic DNA lesions that are repaired via a complex process requiring the coordination of several DNA repair pathways. Defects in ICL repair result in Fanconi anemia, which is characterized by bone marrow failure, developmental abnormalities, and a high incidence of malignancies. SLX4, also known as FANCP, acts as a scaffold protein and coordinates multiple endonucleases that unhook ICLs, resolve homologous recombination intermediates, and perhaps remove unhooked ICLs. In this study, we explored the role of SLX4IP, a constitutive factor in the SLX4 complex, in ICL repair. We found that SLX4IP is a novel regulatory factor; its depletion sensitized cells to treatment with ICL-inducing agents and led to accumulation of cells in the G2/M phase. We further discovered that SLX4IP binds to SLX4 and XPF-ERCC1 simultaneously and that disruption of one interaction also disrupts the other. The binding of SLX4IP to both SLX4 and XPF-ERCC1 not only is vital for maintaining the stability of SLX4IP protein, but also promotes the interaction between SLX4 and XPF-ERCC1, especially after DNA damage. Collectively, these results demonstrate a new regulatory role for SLX4IP in maintaining an efficient SLX4-XPF-ERCC1 complex in ICL repair.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据